midodrine has been researched along with ANS (Autonomic Nervous System) Diseases in 25 studies
Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We describe a man in his 40s with a history of chronic intranasal cocaine use and C5-C7 incomplete quadriplegia complicated by neurogenic orthostatic hypotension, admitted to the intensive care unit for worsening bradycardia and hypotension requiring initiation of dopamine and an increase of his home midodrine dose." | 8.31 | Refractory bradycardia and hypotension in patients with autonomic dysfunction treated with pseudoephedrine. ( Curran, C; Davoudi, F; Foster, G; Gordan, P, 2023) |
| "Midodrine is an alpha-one agonist that produces arterial and venous constriction and leads to a decrease in heart rate by baroreceptor reflexes." | 6.39 | A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. ( Jankovic, J; McElligott, MA; Piwinski, SE, 1994) |
| "We describe a man in his 40s with a history of chronic intranasal cocaine use and C5-C7 incomplete quadriplegia complicated by neurogenic orthostatic hypotension, admitted to the intensive care unit for worsening bradycardia and hypotension requiring initiation of dopamine and an increase of his home midodrine dose." | 4.31 | Refractory bradycardia and hypotension in patients with autonomic dysfunction treated with pseudoephedrine. ( Curran, C; Davoudi, F; Foster, G; Gordan, P, 2023) |
| "Midodrine was found to significantly ameliorate excessive decreases in blood pressure and presyncope during a provocative tilt test." | 2.70 | Midodrine prevents orthostatic intolerance associated with simulated spaceflight. ( Aljuri, N; Bloomfield, D; Cohen, RJ; Maa, M; Mukkamala, R; Mullen, TJ; Ramsdell, CD; Rostoft, S; Sherman, D; Sheynberg, N; Sundby, GH; Toska, K; Williams, GH; Yelle, J, 2001) |
| "Midodrine is a peripherally acting alpha-adrenergic agonist useful in the treatment of NOH." | 2.69 | A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. ( Kaufmann, HC; Low, PA; McElligott, MA; Opfer-Gehrking, TL; Perera, R; Sheng, KN; Wright, RA, 1998) |
| "Ninety-seven patients with orthostatic hypotension were randomized in a 4-week, double-blinded, placebo-controlled study with a 1-week placebo run-in period." | 2.67 | Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. ( Brown, DC; Coghlan, CH; Fouad-Tarazi, FM; Gilden, JL; Hiner, BC; Jankovic, J; Kaufmann, H; Rubin, M, 1993) |
| "In neurogenic orthostatic hypotension (NOH), inadequate vasoconstriction and cardiac output cause BP to drop excessively, resulting in inadequate perfusion, with predictable symptoms such as dizziness, lightheadedness and falls." | 2.52 | Diagnosing and treating neurogenic orthostatic hypotension in primary care. ( Dietrich, E; Espay, AJ; Gelblum, J; Kuritzky, L; Payne, R, 2015) |
| "Neurogenic orthostatic hypotension is often confused with other disorders of orthostatic intolerance, hypovolemic states and systemic conditions." | 2.50 | A practical guide to the treatment of neurogenic orthostatic hypotension. ( Berger, MJ; Kimpinski, K, 2014) |
| "Midodrine is an alpha-one agonist that produces arterial and venous constriction and leads to a decrease in heart rate by baroreceptor reflexes." | 2.39 | A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions. ( Jankovic, J; McElligott, MA; Piwinski, SE, 1994) |
| "In case of orthostatic hypotension with an insufficient increase in heart rate, one has to consider autonomic dysfunction." | 1.72 | [Dizziness upon standing: consider autonomic dysfunction]. ( Bloem, BR; Deinum, J; Riksen, NP; Rutten, J, 2022) |
| "Oral midodrine may further increase ejaculation success, while maintaining autonomy." | 1.35 | Perceived physiological and orgasmic sensations at ejaculation in spinal cord injured men. ( Bélanger, M; Charvier, K; Côté, I; Courtois, F; Fournier, C; Jacquemin, G; Leriche, A; Raymond, D; Vézina, JG, 2008) |
| "Primary Sjogren syndrome is considered as the most frequent connective tissue disease." | 1.33 | [Sjögren's syndrome with autonomic failure and epilepsy]. ( Attout, H; Guez, S; Martre, A; Series, C, 2005) |
| "The diagnosis of chronic fatigue syndrome (CFS) is based on patient history and treatment on cognitive behavior therapy and graded exercise." | 1.32 | Dysautonomia in chronic fatigue syndrome: facts, hypotheses, implications. ( Naschitz, JE; Rosner, I; Yeshurun, D, 2004) |
| "Five patients with idiopathic orthostatic hypotension, two of whom had central nervous system manifestations (Shy-Drager syndrome), were treated with midodrine, an investigational alpha-adrenergic agonist, in a dosage of 2." | 1.26 | Midodrine. A new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome. ( Fealey, RD; Schirger, A; Sheps, SG; Thomas, JE, 1981) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (8.00) | 18.7374 |
| 1990's | 6 (24.00) | 18.2507 |
| 2000's | 11 (44.00) | 29.6817 |
| 2010's | 4 (16.00) | 24.3611 |
| 2020's | 2 (8.00) | 2.80 |
| Authors | Studies |
|---|---|
| Riksen, NP | 1 |
| Rutten, J | 1 |
| Bloem, BR | 1 |
| Deinum, J | 1 |
| Curran, C | 1 |
| Davoudi, F | 1 |
| Foster, G | 1 |
| Gordan, P | 1 |
| Berger, MJ | 1 |
| Kimpinski, K | 1 |
| Kuritzky, L | 1 |
| Espay, AJ | 1 |
| Gelblum, J | 1 |
| Payne, R | 1 |
| Dietrich, E | 1 |
| Asahina, M | 1 |
| Akaogi, Y | 1 |
| Yamanaka, Y | 1 |
| Koyama, Y | 1 |
| Hattori, T | 1 |
| Fischer, PR | 1 |
| Sandroni, P | 3 |
| Pittock, SJ | 1 |
| Porter, CB | 1 |
| Lehwald, LM | 1 |
| Raj, SR | 1 |
| Hohler, AD | 1 |
| Singh, VJ | 1 |
| Goldstein, DS | 1 |
| Holmes, C | 1 |
| Dendi, R | 1 |
| Li, ST | 1 |
| Brentzel, S | 1 |
| Vernino, S | 1 |
| Naschitz, JE | 1 |
| Yeshurun, D | 1 |
| Rosner, I | 1 |
| Schrage, WG | 1 |
| Eisenach, JH | 1 |
| Dinenno, FA | 1 |
| Roberts, SK | 1 |
| Johnson, CP | 1 |
| Low, PA | 3 |
| Joyner, MJ | 1 |
| Attout, H | 1 |
| Martre, A | 1 |
| Guez, S | 1 |
| Series, C | 1 |
| Thijs, RD | 1 |
| van Dijk, JG | 1 |
| Singer, W | 1 |
| Opfer-Gehrking, TL | 2 |
| Suarez, GA | 1 |
| Klein, CM | 1 |
| Hines, S | 1 |
| O'Brien, PC | 1 |
| Slezak, J | 1 |
| Rovit, RL | 1 |
| Courtois, F | 1 |
| Charvier, K | 1 |
| Leriche, A | 1 |
| Vézina, JG | 1 |
| Côté, I | 1 |
| Raymond, D | 1 |
| Jacquemin, G | 1 |
| Fournier, C | 1 |
| Bélanger, M | 1 |
| Schirger, A | 1 |
| Sheps, SG | 1 |
| Thomas, JE | 1 |
| Fealey, RD | 1 |
| Piwinski, SE | 1 |
| Jankovic, J | 2 |
| McElligott, MA | 2 |
| Gilden, JL | 1 |
| Hiner, BC | 1 |
| Kaufmann, H | 2 |
| Brown, DC | 1 |
| Coghlan, CH | 1 |
| Rubin, M | 1 |
| Fouad-Tarazi, FM | 1 |
| Mallipeddi, R | 1 |
| Mathias, CJ | 1 |
| Wright, RA | 1 |
| Kaufmann, HC | 1 |
| Perera, R | 1 |
| Sheng, KN | 1 |
| Grubb, BP | 1 |
| Karas, B | 1 |
| Kosinski, D | 1 |
| Boehm, K | 1 |
| Hirayama, M | 2 |
| Koike, Y | 2 |
| Ieda, T | 1 |
| Takahashi, A | 2 |
| Sobue, G | 1 |
| Ramsdell, CD | 1 |
| Mullen, TJ | 1 |
| Sundby, GH | 1 |
| Rostoft, S | 1 |
| Sheynberg, N | 1 |
| Aljuri, N | 1 |
| Maa, M | 1 |
| Mukkamala, R | 1 |
| Sherman, D | 1 |
| Toska, K | 1 |
| Yelle, J | 1 |
| Bloomfield, D | 1 |
| Williams, GH | 1 |
| Cohen, RJ | 1 |
| Watanabe, H | 1 |
| Kaneoke, Y | 1 |
| Brannan, T | 1 |
| Krakoff, L | 1 |
| Yahr, MD | 1 |
| Mandeli, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Plasma Exchange for Autoimmune Autonomic Failure[NCT00359346] | 3 participants | Observational | 2006-07-14 | Completed | |||
| Dose Response to the Norepinephrine Precursor Droxidopa in Hypotensive Individuals With Spinal Cord Injury[NCT03602014] | Phase 4 | 22 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study[NCT02308124] | Phase 4 | 87 participants (Actual) | Interventional | 2014-11-30 | Completed | ||
| Efficacy and Safety of Midodrine and Atomoxetine Treatment in Patients With Neurogenic Orthostatic Hypotension : A Prospective Randomized Study[NCT03350659] | Phase 4 | 50 participants (Actual) | Interventional | 2018-01-01 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Change of the depression score after 3-month medical treatment compared to initial results.~21 multiple-choice questions, each of which can be scored from 0 to 3. Higher score represent higher degree of depression.~Score Normal; 0-13, Mild depression; 14-19, Moderate depression; 20-28, Severe depression; 29-63" (NCT02308124)
Timeframe: after 3-month medical treatment.
| Intervention | points (Mean) |
|---|---|
| Midodrine Only | -6.8 |
| Pyridostigmine Only | -7.8 |
| Midodrine + Pyridostigmine | -3.5 |
"Change of the OH associated symptom survey result after 3-month medical treatment compared to initial results.~OHQ questionnaire has two components: the OH daily activity scale (OHDAS), which contains 4 items measuring the impact of OH on daily activities, and the OH symptom assessment (OHSA), which contains 6 items measuring the symptoms of OH (dizziness/light headedness, vision disturbance, weakness, fatigue, trouble concentrating, and head/neck discomfort).This questionnaire reflects the severity of OH-related symptoms on a 10-point scale, with 0 indicating the absence of a symptom and 10 indicating maximal severity.~** OHQ total score minimal 0 ~ maximal 100" (NCT02308124)
Timeframe: after 3-month medical treatment.
| Intervention | points (Mean) |
|---|---|
| Midodrine Only | -16.2 |
| Pyridostigmine Only | -17.2 |
| Midodrine + Pyridostigmine | -12.6 |
"changes in Short Form (36) Health Survey version 2 (SF-36v2) mental component summary scale (MCS)~SF-36v2 measures eight HRQOL domains (physical functioning, role limitation caused by physical problems, bodily pain, general health, vitality, social functioning, role limitation caused by emotional problems, and mental health) summarized into two summary scales that are normalized to the population (mean=50, standard deviation=10): the physical component summary scale (PCS) and the mental component summary scale (MCS).20 Better HRQOL is reflected by higher SF-36v2 scores." (NCT02308124)
Timeframe: changes at 3 months after treatment
| Intervention | points (Mean) |
|---|---|
| Midodrine Only | 5.0 |
| Pyridostigmine Only | 6.7 |
| Midodrine + Pyridostigmine | 0.4 |
"changes in Short Form (36) Health Survey version 2 (SF-36v2) physical component summary scale (PCS) compared to the baseline~SF-36v2 measures eight HRQOL domains (physical functioning, role limitation caused by physical problems, bodily pain, general health, vitality, social functioning, role limitation caused by emotional problems, and mental health) summarized into two summary scales that are normalized to the population (mean=50, standard deviation=10): the physical component summary scale (PCS) and the mental component summary scale (MCS).20 Better HRQOL is reflected by higher SF-36v2 scores." (NCT02308124)
Timeframe: changes at 3 months after treatment
| Intervention | points (Mean) |
|---|---|
| Midodrine Only | 5.6 |
| Pyridostigmine Only | 4.2 |
| Midodrine + Pyridostigmine | 2.7 |
Change of orthostatic SBP and DBP drop after 3-month medical treatment compared to initial results. (NCT02308124)
Timeframe: after 3-month medical treatment
| Intervention | mmHg (Mean) | |
|---|---|---|
| Changes in SBP drop | Changes in DBP drop | |
| Midodrine + Pyridostigmine | 8.9 | 7.4 |
| Midodrine Only | 11.1 | 7.5 |
| Pyridostigmine Only | 13.6 | 11.1 |
3 reviews available for midodrine and ANS (Autonomic Nervous System) Diseases
| Article | Year |
|---|---|
A practical guide to the treatment of neurogenic orthostatic hypotension.
Topics: Autonomic Nervous System Diseases; Central Nervous System Neoplasms; Cholinesterase Inhibitors; Dise | 2014 |
Diagnosing and treating neurogenic orthostatic hypotension in primary care.
Topics: Accidental Falls; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Disease Management; Dr | 2015 |
A comparison of postspace-flight orthostatic intolerance to vasovagal syncope and autonomic failure and the potential use of the alpha agonist midodrine for these conditions.
Topics: Adult; Aged; Autonomic Nervous System Diseases; Blood Pressure; Female; Heart Rate; Humans; Hypotens | 1994 |
9 trials available for midodrine and ANS (Autonomic Nervous System) Diseases
| Article | Year |
|---|---|
Effects of midodrine on exercise-induced hypotension and blood pressure recovery in autonomic failure.
Topics: Adrenergic alpha-Agonists; Aged; Autonomic Nervous System Diseases; Bicycling; Blood Pressure; Cardi | 2004 |
Pyridostigmine treatment trial in neurogenic orthostatic hypotension.
Topics: Adolescent; Adult; Arteries; Autonomic Nervous System Diseases; Baroreflex; Cholinergic Fibers; Chol | 2006 |
Pyridostigmine treatment trial in neurogenic orthostatic hypotension.
Topics: Adolescent; Adult; Arteries; Autonomic Nervous System Diseases; Baroreflex; Cholinergic Fibers; Chol | 2006 |
Pyridostigmine treatment trial in neurogenic orthostatic hypotension.
Topics: Adolescent; Adult; Arteries; Autonomic Nervous System Diseases; Baroreflex; Cholinergic Fibers; Chol | 2006 |
Pyridostigmine treatment trial in neurogenic orthostatic hypotension.
Topics: Adolescent; Adult; Arteries; Autonomic Nervous System Diseases; Baroreflex; Cholinergic Fibers; Chol | 2006 |
Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine.
Topics: Adult; Aged; Aged, 80 and over; Autonomic Nervous System Diseases; Double-Blind Method; Female; Huma | 1993 |
A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Autonomic Nervous System Diseases; Cross-Over Studies; Dose- | 1998 |
A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Autonomic Nervous System Diseases; Cross-Over Studies; Dose- | 1998 |
A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Autonomic Nervous System Diseases; Cross-Over Studies; Dose- | 1998 |
A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension.
Topics: Adrenergic alpha-Agonists; Adult; Aged; Autonomic Nervous System Diseases; Cross-Over Studies; Dose- | 1998 |
Preliminary observations on the use of midodrine hydrochloride in the treatment of refractory neurocardiogenic syncope.
Topics: Administration, Oral; Adolescent; Adrenergic alpha-Agonists; Adult; Aged; Autonomic Nervous System D | 1999 |
[A one-month combined use of selective adrenergic beta 1- and alpha 1-agonists for postprandial hypotension in patients with autonomic failure].
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Aged; Autonomic Nervous System Diseases; Chroni | 2000 |
Midodrine prevents orthostatic intolerance associated with simulated spaceflight.
Topics: Adrenergic alpha-Agonists; Adult; Autonomic Nervous System Diseases; Bed Rest; Hemodynamics; Humans; | 2001 |
[Effect of combined therapy with selective beta 1- and alpha 1-adrenergic agonists upon postprandial hypotension in patients with progressive autonomic failure].
Topics: Administration, Oral; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Adult; Autonomic Nervous | 1992 |
Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine).
Topics: Adrenergic alpha-Agonists; Aged; Autonomic Nervous System Diseases; Clinical Trials as Topic; Double | 1988 |
13 other studies available for midodrine and ANS (Autonomic Nervous System) Diseases
| Article | Year |
|---|---|
[Dizziness upon standing: consider autonomic dysfunction].
Topics: Aged; Autonomic Nervous System Diseases; Blood Pressure; Dizziness; Humans; Hypotension, Orthostatic | 2022 |
Refractory bradycardia and hypotension in patients with autonomic dysfunction treated with pseudoephedrine.
Topics: Autonomic Nervous System Diseases; Bradycardia; Dopamine; Humans; Hypotension; Hypotension, Orthosta | 2023 |
Differences in skin sympathetic involvements between two chronic autonomic disorders: multiple system atrophy and pure autonomic failure.
Topics: Aged; Autonomic Nervous System Diseases; Blood Flow Velocity; Blood Pressure; Female; Fludrocortison | 2009 |
Isolated sympathetic failure with autoimmune autonomic ganglionopathy.
Topics: Adolescent; Autoantibodies; Autonomic Nervous System Diseases; Humans; Immunoglobulins, Intravenous; | 2010 |
Probable hereditary multiple system atrophy-autonomic (MSA-A) in a family in the United States.
Topics: Adrenergic alpha-Agonists; Aged, 80 and over; Anti-Inflammatory Agents; Autonomic Nervous System Dis | 2012 |
Pandysautonomia associated with impaired ganglionic neurotransmission and circulating antibody to the neuronal nicotinic receptor.
Topics: Adrenergic alpha-Agonists; Aged; Autoantibodies; Autoimmune Diseases; Autonomic Nervous System; Auto | 2002 |
Dysautonomia in chronic fatigue syndrome: facts, hypotheses, implications.
Topics: Arrhythmias, Cardiac; Autonomic Nervous System Diseases; Diagnosis, Differential; Evidence-Based Med | 2004 |
[Sjögren's syndrome with autonomic failure and epilepsy].
Topics: Aged; Anti-Inflammatory Agents; Anticonvulsants; Autonomic Nervous System Diseases; Electromyography | 2005 |
Stress induced hypotension in pure autonomic failure.
Topics: Autonomic Nervous System Diseases; Catecholamines; Female; Humans; Hypotension, Orthostatic; Middle | 2006 |
Autonomic failure: observations of a physician-patient.
Topics: Aged, 80 and over; Antibodies; Autoimmune Diseases; Autonomic Nervous System Diseases; Drug Therapy, | 2007 |
Perceived physiological and orgasmic sensations at ejaculation in spinal cord injured men.
Topics: Adolescent; Adrenergic alpha-Agonists; Adult; Autonomic Dysreflexia; Autonomic Nervous System Diseas | 2008 |
Midodrine. A new agent in the management of idiopathic orthostatic hypotension and Shy-Drager syndrome.
Topics: Adult; Aged; Autonomic Nervous System Diseases; Blood Pressure; Ethanolamines; Female; Humans; Hypot | 1981 |
Raynaud's phenomenon after sympathetic denervation in patients with primary autonomic failure: questionnaire survey.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Autonomic Nervous System Diseases; Cold Temperature; | 1998 |